First Time Loading...
C

Clarus Therapeutics Holdings Inc
NASDAQ:CRXT

Watchlist Manager
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Watchlist
Price: 0.021 USD -19.54%
Updated: May 15, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

48.9m
+34%
Assets
Growth Rates:
1 Year
+73%
3 Years
-
5 Years
-
7 Years
-
10 Years
-
62m
-7%
Liabilities
Growth Rates:
1 Year
-67%
3 Years
-
5 Years
-
7 Years
-
10 Years
-
-13.1m
+57%
Equity
Growth Rates:
1 Year
+92%
3 Years
-
5 Years
-
7 Years
-
10 Years
-

Balance Sheet Decomposition
Clarus Therapeutics Holdings Inc

48.9m
Assets
62m
Liabilities
48.9m
Assets
62m
Liabilities
Current Assets 48.9m
Cash & Short-Term Investments 19.2m
Receivables 8.7m
Other Current Assets 21m
Non-Current Assets 60k
PP&E 60k
Current Liabilities 61.8m
Accounts Payable 8.5m
Accrued Liabilities 9.8m
Other Current Liabilities 43.5m
Non-Current Liabilities 197k
Other Non-Current Liabilities 197k

Balance Sheet
Clarus Therapeutics Holdings Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2019 Dec-2020 Dec-2021
Assets
Cash & Cash Equivalents
2
7
26
Cash Equivalents
2
7
26
Total Receivables
0
4
6
Accounts Receivables
0
4
6
Other Receivables
0
0
0
Inventory
7
6
14
Other Current Assets
1
2
5
Total Current Assets
10
19
52
PP&E Net
0
0
0
PP&E Gross
0
0
0
Accumulated Depreciation
0
0
0
Total Assets
10
N/A
19
+97%
52
+167%
Liabilities
Accounts Payable
4
12
14
Accrued Liabilities
2
5
8
Short-Term Debt
0
0
0
Current Portion of Long-Term Debt
71
42
42
Other Current Liabilities
0
1
2
Total Current Liabilities
77
60
66
Long-Term Debt
0
78
0
Other Liabilities
66
9
2
Total Liabilities
143
N/A
147
+3%
68
-54%
Equity
Common Stock
184
198
0
Retained Earnings
316
326
322
Additional Paid In Capital
0
0
306
Total Equity
133
N/A
128
+4%
16
+88%
Total Liabilities & Equity
10
N/A
19
+97%
52
+167%
Shares Outstanding
Common Shares Outstanding
22
22
22

See Also

Summary
CRXT intrinsic value, competitors valuation, and company profile.
DCF Valuation
CRXT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CRXT stock valuation using valuation multiples.
Wall Street Estimates
CRXT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CRXT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.